Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 165 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antiemetic Clear all
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT06428409
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Interventions
Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin, Rescue medication, Supportive care measures, Cisplatin, Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

NCT01054456
View directory record Official record
Conditions
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
Interventions
palonesetron
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Sunrise, Florida • Galesburg, Illinois • Skokie, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Phase 3 Interventional

Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer

NCT00020657
View directory record Official record
Conditions
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dolasetron mesylate, granisetron hydrochloride, ondansetron, prochlorperazine, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 22, 2026, 11:07 PM EDT
Recruiting Phase 2 Interventional

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

NCT05317000
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Combination 5-azacytidine and nivolumab, Nivolumab
Drug
Lead sponsor
Barbara Burtness
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT01829503
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
decitabine and cytarabine, Supportive Care
Drug · Other
Lead sponsor
Annie Im, M.D.
Other
Eligibility
60 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 22, 2026, 11:07 PM EDT
Withdrawn Not applicable Interventional

Relief Band as an Adjunct to Antiemetic Therapy in Patients Who Receive Mod to Highly Emetogenic Chemotherapy

NCT01980160
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Activated Nometex Device, Unactivated Nometex Device
Device
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years to 100 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

NCT00186628
View directory record Official record
Conditions
Leukemia, Mast-Cell, Mantle-cell Lymphoma
Interventions
Total lymphoid irradiation, Rituximab, Anti-thymoglobulin, rabbit (ATG, rabbit ATG), Cyclosporine, Mycophenylate mofetil, Filgrastim, Granisetron, Solumedrol, Acetaminophen, Diphenhydramine, Hydrocortisone
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 76 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Not applicable Interventional

Reducing Up-set Stomach and Vomiting After Surgery Using Essential Oils

NCT03370328
View directory record Official record
Conditions
Nausea
Interventions
Peppermint oil, Ginger oil
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

NCT02780609
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Melphalan, Dexamethasone, Autologous Hematopoietic Cell Transplantation (HCT), Fosaprepitant
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Not applicable Interventional Results available

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

NCT01640340
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
aprepitant, palonosetron hydrochloride, ondansetron, dexamethasone
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 88 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Oct 22, 2026, 11:07 PM EDT
Withdrawn Not applicable Interventional

Does Dexamethasone Administration Improve Recovery In Patients Undergoing Minimally Invasive Sacrocolpopexy?

NCT03094442
View directory record Official record
Conditions
Quality of Life, Pelvic Organ Prolapse, Prolapses, Vaginal Vault
Interventions
Dexamethasone, Normal saline
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

NCT02504489
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Docetaxel + Plinabulin (DP), Docetaxel (D)
Drug
Lead sponsor
BeyondSpring Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
19
States / cities
Chandler, Arizona • Anaheim, California • Whittier, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 22, 2026, 11:07 PM EDT
Recruiting Phase 2 Interventional

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

NCT04332874
View directory record Official record
Conditions
Sarcoma, Myxofibrosarcoma, Undifferentiated Pleomorphic Sarcoma, Alveolar Soft Part Sarcoma
Interventions
Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 22, 2026, 11:07 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

NCT00430183
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, LHRH agonist, surgery
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
221
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Berkeley, California + 166 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial

NCT02456662
View directory record Official record
Conditions
Drug-induced Nausea and Vomiting
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
319 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

NCT02578732
View directory record Official record
Conditions
Locally Advanced Pancreatic Cancer, Pancreatic Cancer
Interventions
FOLFOXA
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Phase 1 Interventional

Cancer Stem Cell High-Throughput Drug Screening Study

NCT02654964
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Combination Drug Therapy
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

NCT01534637
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
aprepitant, gemcitabine hydrochloride, capecitabine, fluorouracil, radiation therapy, questionnaire administration, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications
Drug · Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 22, 2026, 11:07 PM EDT
Active, not recruiting Phase 1 Interventional

iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma

NCT01953900
View directory record Official record
Conditions
Osteosarcoma, Neuroblastoma
Interventions
GD2 T cells, VZV vaccine, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2034
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 22, 2026, 11:07 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

NCT04216329
View directory record Official record
Conditions
Gliosarcoma, Newly Diagnosed, Glioblastoma
Interventions
Selinexor, Temozolomide, Generic Radiation therapy (RT), Selective serotonin receptor (5-HT3) antagonists, Olanzapine, Salt tablets, Anti-diarrheal
Drug · Radiation · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Not applicable Interventional

Stress Management Training for Latinas Receiving Chemotherapy

NCT01599520
View directory record Official record
Conditions
Cancer, Stress
Interventions
Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT), Usual Care Only
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults

NCT07226362
View directory record Official record
Conditions
Safety, and Tolerability
Interventions
DHE inhalation powder low dose administered via dry powder inhaler (DPI) device, DHE inhalation powder high dose administered via dry powder inhaler (DPI) device, DHE injected intravenously (1 mg), DHE 2 mg administered by nasal spray (Migranal®), Metoclopramide 10mg
Combination Product · Drug
Lead sponsor
Aspeya Switzerland SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 22, 2026, 11:07 PM EDT
Terminated Phase 1 Interventional

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

NCT01649258
View directory record Official record
Conditions
Breast Cancer, Nausea, Vomiting
Interventions
granisetron transdermal system, fosaprepitant dimeglumine, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 22, 2026, 11:07 PM EDT
Completed Phase 4 Interventional Results available

Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade

NCT01335542
View directory record Official record
Conditions
Readiness to Discharge
Interventions
Peri-Articular Injection, Epidural Pathway (PCEA+FNB)
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 22, 2026, 11:07 PM EDT